The only SNP-based NIPT delivers more insights with high accuracy1,2
- validated in the largest prospective NIPT study ever
- the only NIPT that distinguishes the pregnant person’s DNA from baby’s DNA
- the approach that creates unique, clinically validated capabilities
Panorama evaluates SNPs— the 1% of our DNA that makes us different from one another
A Trusted Resource
- Validated in SMART, the largest prospective NIPT study with over 20,000 participants enrolled.
- More than 3 million people in more than 60 countries have chosen Panorama for genetic testing during pregnancy.
- Panorama has been evaluated in 25+ peer-reviewed publications and in more than 1.3 million pregnancies.
- Panorama offers complimentary pre- and post-test information sessions with board-certified genetic counselors.
- Panorama is performed from a simple blood draw of the pregnant person and poses no risk to the pregnancy.
Panorama is a screening test, which means that this test does not make a final diagnosis. A high risk result means that your pregnancy has a higher chance of having a specific genetic condition. However, you cannot know for sure if your baby has that condition based upon the screening result alone. All medical decisions should be made after discussion with your healthcare provider regarding diagnostic testing during the pregnancy, like chorionic villus sampling (CVS) or amniocentesis, or testing the baby after birth.
Findings from the SMART study have now been published in the American Journal of Obstetrics and Gynecology
Authors: Pe’er Dar, MD | Bo Jacobsson, MD, PhD | Rebecca Clifton, PhD | Charlly Kao, PhD | Hakon Hakonarson, MD, PhD | Mary E. Norton, MD
Open Access: Published: January 13, 2022
Authors: Pe’er Dar, MD | Bo Jacobsson, MD, PhD | Cora MacPherson, PhD | Charlly Kao, PhD | Hakon Hakonarson, MD, PhD | Mary E. Norton, MD
Open Access: Published: January 24, 2022
Panorama offers prenatal screening for twin, egg donor, and gestational carrier pregnancies
Conditions screened in twin, egg donor, and gestational carrier pregnancies:
- Trisomy 21*
- Trisomy 18*
- Trisomy 13*
- Sex chromosome trisomies (reported when seen)**
- 22q11.2 deletion syndrome (optional)**
Complete Test Specifications for Singleton, Egg Donor, Gestational Carrier, and Monozygotic (Identical) Twins
Definition of performance terms
Sensitivity is the ability to correctly identify a truly high risk case as high risk. For example, in a group of Trisomy 21 cases, Panorama will correctly identify more than 99% of those cases.
Specificity is the ability to correctly identify an unaffected case as low risk.
Positive Predictive Value (PPV) is the likelihood the result says high risk and the fetus is actually affected. For example, when Panorama shows a high risk result for Trisomy 21, there is a 95% chance that the fetus is affected by Trisomy 21. In other words, 5% of the time, you could get a high risk result when the fetus is not affected by Trisomy 21.
Negative Predictive Value (NPV) is the likelihood the result says low risk and the fetus is truly not affected.
|Condition||Sensitivity (95% CI)||Specificity (95% CI)||PPV||NPV|
|Trisomy 21*2,4||99.0% (CI 97.1-100)||>99% (CI 99.93-99.99)||95%||>99.99%‡|
|Trisomy 18*2,4||94.1% (CI 82.9-100)||>99% (CI 99.96-100)||91%||>99.99%‡|
|Trisomy 13*2,4||>99% (CI 73.5-100)||>99% (CI 99.96-100)||68%||>99.99%‡|
|Monosomy X**4–7||94.7% (CI 74.0-99.9)||>99% (CI 99.7-100)||78%||>99.99%‡|
|Triploidy**8,9||>99% (CI 66.4-100)||>99% (CI 99.5-100)||11%||>99.99%‡|
|XXX, XXY, XYY**10||73.1% (CI 61.0-85.1)||99.9% (CI 99.90-99.99)||86.4%||99.87%‡|
|22q11.2 deletion syndrome**11||83.3% (CI 51.6-97.9)||>99% (CI 99.91-99.98)||53%||99.9%||(CI 99.9-100)|
|1p36 deletion syndrome**12,13||>99% (CI 2.5-100)||>99% (CI 99.1-100)||7-17%||||99.98-99.99%|||
|Angelman syndrome**†12,13||95.5% (CI 77.2-99.9)||>99% (CI 99.1-100)||10%§||>99.99%|
|Cri-du-chat syndrome**12,13||>99% (CI 85.8-100)||>99% (CI 99.1-100)||2-5%||||>99.99%|
|Prader-Willi syndrome**†12,13||93.8% (CI 69.8-99.8)||>99% (CI 99.1-100)||5%||>99.99%|
|Female5,6,7||>99.9% (CI 99.4-100)||>99.9% (CI 99.5-100)|
|Male5,6,7||>99.9% (CI 99.5-100)||>99.9% (CI 99.4-100)|
Test Specifications for Dizygotic (Nonidentical) Twins3
Is Panorama right for you?
We’re here to help you find out
1ACOG Practice Bulletin 226. Obstet Gynecol. 2020 Oct;136(4):859-867.
2Dar et al. Am J Obstet Gynecol. 2022 Aug;227(2):259.e1-259.e14.
3Natera internal data on file.
4DiNonno et al. J Clin Med. 2019 Aug 26;8(9):1311.
5Nicolaides et al. Prenat Diagn. 2013 June;33(6):575-9.
6Pergament et al. Obstet Gynecol. 2014 Aug;124(2 Pt 1):210-8.
7Ryan et al. Fetal Diagn Ther. 2016;40(3):219-223.
8Nicolaides et al. Fetal Diagn Ther. 2014. 35;(3):212-7.
9Kantor et al. Prenat Diagn. 2022;42:994–999.
10Martin et al. 25th International Conference on Prenatal Diagnosis and Therapy Meeting; June 6-8, 2021.
11Dar et al. Am J Obstet Gynecol. 2022 Jul;227(1):79.e1-79.e11.
12Martin et al. Clin Genet. 2018 Feb;93(2):293-300.
13Wapner et al. Am J Obstet Gynecol. 2015 Mar;212(3):332.e1-9.
* CA residents: If your clinician ordered screening through the California Prenatal Screening program using Natera's Vasistera™ NIPT, Panorama™ will only screen for supplemental conditions. If this is the case, trisomies 21, 18 and 13, and fetal sex (optional) will be screened using Vasistera™ NIPT and will be reported separately.
** Not available for egg-donor or gestational carrier pregnancies or in cases of dizygotic (nonidentical) twins. Triploidy and microdeletions except for 22q11.2 deletions are not available for monozygotic (identical) twins.
† This test has been validated on full region deletions of Prader-Willi syndrome/Angelman syndrome (PWS/AS) only and might be unable to detect smaller deletions. It has not been validated for other molecular mechanisms which could cause PWS/AS such as uniparental disomy (UPD) or methylation.
‡ Ongoing clinical follow-up is performed to ensure the NPV does not fall below the quoted value but follow up is not obtained for all low risk calls.
§ PPV for 22q11.2 deletion syndrome and Angelman syndrome in published studies was 53% and 10% respectively when no ultrasound anomalies were seen and was up to 100% when ultrasound anomalies were seen prior to testing.
|| Dependent upon fetal fraction (FF). For 22q11.2 deletion syndrome, only the paternal allele is evaluated at FF ≤ 6.5%. For 1p36 deletion syndrome and Cri-du-chat syndrome, only the paternal allele is evaluated at FF < 7%. For Angelman syndrome, no risk assessment is reported at FF < 7%. For Prader-Willi syndrome, no risk assessment is reported at FF ≤ 2.8%.